An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Older women who have been diagnosed with an irregular heart beat are at higher risk of stroke than men. A new study led by the Research Institute of the McGill University Health Centre (RI MUHC) shows that warfarin, the most common anticoagulant therapy used to prevent stroke in patients with Atrial fibrillation (AF) may not be as effective in women, 75 years or older, as in men.
In a study that examined use of the anticoagulant medication warfarin and risk of stroke following a diagnosis of atrial fibrillation in older patients, women, especially those 75 years or older, had a higher risk of stroke than men, regardless of their risk profile and use of warfarin, suggesting that current anticoagulant therapy to prevent stroke might not be sufficient for older women, according to a study in the May 9 issue of JAMA.
Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, announced today at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, FDA approval and commercial launch of the PARADYM RF family of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT-D) devices.
Massachusetts Governor Deval Patrick has proclaimed May to be Cardiac Arrhythmia Awareness Month, calling attention to the need for greater public awareness throughout the Commonwealth about two serious heart rhythm conditions, atrial fibrillation and sudden cardiac arrest. To support consumer education about these potentially life-threatening disease states, the Heart Rhythm Society (HRS) has launched a Boston Citywide Awareness Campaign to increase knowledge about symptoms, warning signs and available treatment options.
Every thought, every movement, every heartbeat is controlled by lightning-quick electrical impulses in the brain, the muscles, and the heart. But too much electrical excitability in the membranes of the cells can cause things like epilepsy and cardiac arrhythmia. A research group at Linköping University has now published new discoveries that can lead to new medicines for these diseases.
Alcohol use in Bollywood movies is directly influencing the drinking habits of India's adolescents, according to a new study presented today at the World Congress of Cardiology in Dubai.
St. Jude Medical, Inc., a global medical device company, today announced CE Mark Approval of the Ellipse implantable cardioverter defibrillator (ICD). Designed with feedback from more than 200 physicians from around the world, the Ellipse ICD provides the benefits of advanced features and power in the industry's smallest high-energy ICD.
Boston Scientific Corporation announces the U.S. market launch of its Z Flex-270 Steerable Sheath. The device is intended for use in a wide range of electrophysiology (EP) procedures to facilitate the introduction and placement of diagnostic and therapeutic catheters within the heart.
Heart cells starved of nutrients are less likely to be damaged during periods of decreased blood flow and sudden influxes of blood, known as ischemia and reperfusion, and are also less likely to get out of synch with their cellular neighbors, the damaging phenomenon called arrhythmia.
Estech, a leader in minimally invasive and endoscopic cardiac ablation, announced today that the Food and Drug Administration (FDA) has given conditional Investigational Device Exemption (IDE) approval to initiate patient enrollment in the Estech-sponsored ATTAC-AF trial.
Cardiomyopathy comprises a deterioration of the heart muscle that affects the organ's ability to efficiently pump blood through the body. Previously researchers have tied forms of the disease to the alternative splicing of titin, a giant protein that determines the structure and biomechanical properties of the heart, but the molecular mechanism remained unknown.
High-fat, low-carb foods are a popular choice for dieters, but new laboratory research by University of Alabama at Birmingham cardiologists indicates these may be detrimental to the health of people who have ischemic cardiovascular disease or a predisposition to heart attacks.
XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally.
The Canadian Journal of Cardiology has published a focused update to the Canadian Cardiovascular Society's atrial fibrillation guidelines.
Biomedical Systems, a global provider of cardiac diagnostic services and products, has introduced the TruVue® Wireless Ambulatory ECG Monitoring System for the diagnosis and management of atrial fibrillation and other complex cardiac arrhythmia.
Boston Scientific Corporation announces the exercise of its option to acquire Cameron Health, Inc., a privately held company based in San Clemente, California.
As part of its continued commitment to ADHD research, Shire plc, the global specialty biopharmaceutical company, today announced it is initiating two Phase 4 clinical trials to compare Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta (methylphenidate HCl) Extended-Release Tablets.
Pediatric cardiology researchers and clinicians from almost 50 centers from across the U.S. and around the world are gathering at the Cardiology 2012 Conference sponsored by The Children's Hospital of Philadelphia on Feb. 22-26 in Orlando, Fla.
How much calcium could a hibernating woodchuck's heart cells sequester, if a hibernating woodchuck's heart cells could sequester calcium? More than enough, it turns out, to protect the animals from cardiac arrhythmias - abnormal heart rhythms such as ventricular tachycardia and ventricular fibrillation that can lead to sudden cardiac death - according to a new study of the hibernating animals that may provide insight into arrhythmia therapies.
Researchers have found that a biological clock can influence a heart attack. The risk of “sudden cardiac death” peaks in the morning and rises again in the evening as shown in lab animals.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.